This is possibly the award that our team here at CiteAb are most passionate about. Past winners have included Thermo Fisher Scientific’s 2-part Validation Approach (2018), Abcam’s Knockout validation initiative (2017), and Proteintech’s RNA interference (RNAi) technology in 2016.
This year our judges were looking for the most exciting new initiatives in the sector in which most work was completed between January 2018 and December 2018.
We’re thrilled to announce that Cell Signaling Technology has been awarded Antibody validation initiative of the year for 2019, for the company’s efforts in proactively engaging in a number of validation initiatives designed to improve the quality and quantity of data available to its customers.
Approximately 50 per cent of Cell Signaling Technology’s catalog (and about 70 per cent of its monoclonal antibodies) have been validated in accordance with the five-pillar model proposed by Uhlen et al. This means that more than two thirds of its monoclonal antibodies have been validated using a knockout model, binary model (positive/negative), CRISPR/Cas9 or siRNA based platform.
Beginning in 2018, Cell Signaling Technology quietly launched initiatives to expand this coverage to 80-90 per cent of its products, more than most other companies.
A spokesperson for the company told us: “Since our inception in 1999, we've believed that using a positive and negative model in EVERY application is the only appropriate way to validate an antibody - this mission has not changed but has advanced with technology over the years. Going forward, Cell Signaling Technology promises to make even more data available to customers, be more transparent with testing results - including applications that were tested and failed - and to continue to work with antibody users to ensure that their experiments are a success.”
Dr Andrew Chalmers, founder of CiteAb, said: “Cell Signaling Technology’s efforts in antibody validation have been extensive and wide reaching, and while it may not have a flashy name for a company-branded process, it is working to use the very best techniques available and to roll these out across huge amounts of its portfolio, making a big difference to validation levels and to the reproducibility of results. Congratulations to all of the team at Cell Signaling Technology.”
Explore additional categories featuring in the 2019 CiteAb Awards.
Highlighting an outstanding individual who has made a significant impact in the reagent sector.
Shedding light on the reagent supplier that researchers have been most impressed by in 2018.
Recognising the most exciting new antibody validation initiative in the sector from 2018.
Celebrating reagents or instruments launched in the last year that are set to change the sector.
An exciting award for the company with the largest percentage increase in citations during the previous year.
A new award which really distinguishes the best of the best - the company with the most citations across antibodies, ELISA kits, biochemicals and instruments.
The supplier with the largest percentage increase in biochemicals during the previous year.
Recognising the most successful antibody company providing secondary antibodies based on CiteAb data.
A brand new award putting the spotlight on the supplier with the most antibody citations related to plant science.
An award for the flow cytometer machine with the greatest percentage increase in citations in the previous year.
A brand new award recognising the antibody supplier with the largest increase in citations in immunology over the last three years.
A new award based on CiteAb’s new Kits and Assays data, highlighting the company with the most ELISA kit citations.
Another new award, this category will highlight the supplier with the largest percentage increase in ELISA kit citations over the past year.
This award highlights the supplier with the largest percentage of its total citations being for IHC - a true specialist in the field.
This year we’re looking to highlight the company with the largest increase in citations in Japan.